- $261.42bn
- $287.24bn
- $54.07bn
- 91
- 34
- 75
- 76
REG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Annual Financial Report
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Final Results
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi recommended for EU approval for LS-SCLC
AnnouncementREG - AstraZeneca PLC - Enhertu approved in US for breast cancer post ET
AnnouncementREG - AstraZeneca PLC - Dato-DXd approved in US for HR+ breast cancer
AnnouncementREG - AstraZeneca PLC - Calquence combination approved in US for 1L MCL
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Dato-DXd NSQ NSCLC application withdrawn in EU
AnnouncementREG - AstraZeneca PLC - Tagrisso approved in EU based on LAURA trial
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in US for limited-stage SCLC
AnnouncementREG - AstraZeneca PLC - AstraZeneca appoints Iskra Reic EVP International
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Truqap improved rPFS in advanced prostate cancer
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
Announcement